Engineered LP8 mini-tag boosts liraglutide precursor yield to 133 mg/L in E. coli
Background
Treatment for Type 2 diabetes mellitus (T2DM) often utilizes Glucagon-like peptide-1 (GLP-1) analogs like liraglutide, an incretin hormone known for its glucose-dependent insulinotropic activity. However, producing small peptides such as GLP-1 in microbial systems like Escherichia coli is challenging due to their susceptibility to proteolytic degradation, leading to low manufacturing yields. While fusion protein tags can enhance stability during purification, excessively large tags often reduce the overall target peptide yield, especially when the peptide is significantly smaller than its fusion partner. This creates a critical need for optimized, compact fusion tag strategies to improve recombinant peptide production efficiency.
Study Design
Researchers engineered 11 novel cleavable fusion tag constructs (LP1-LP11) to optimize the recombinant expression of Arg34-GLP-1(7-37) (a liraglutide precursor) in E. coli. Each construct varied only in its mini-tag design, ranging from 11 to 125 amino acids in length. The expression vector incorporated a T7 leader sequence for enhanced translational initiation, 6xHis/6xArg affinity tags for purification, and TEV protease cleavage sites to release the target peptide. The primary objective was to identify a compact tag that maximized the mass fraction of the target peptide while maintaining efficient inclusion body formation.
Results
Among the 11 engineered tags, LP8, featuring a compact 4.0 kDa tag, demonstrated superior performance. It achieved the highest fusion protein expression, yielding 133 mg/L of the fusion protein. Based on mass fraction, this translated to a calculated liraglutide precursor yield of 60 mg/L, representing 45% of the total fusion mass. After RP-HPLC purification, an actual recovered yield of 14.6 mg/L of the liraglutide precursor was obtained. This high yield was primarily attributed to efficient inclusion body formation (>95% insolubility) and enhanced translational initiation driven by the T7 leader sequence. The identity and sequence integrity of the purified peptide were rigorously confirmed through LC/MS analysis, validating the successful production of the liraglutide precursor.
Key Findings
- Engineered LP8 mini-tag achieved 133 mg/L fusion protein expression in E. coli.
- Calculated liraglutide precursor yield was 60 mg/L, representing 45% of the fusion mass.
- Actual recovered liraglutide precursor yield after RP-HPLC purification was 14.6 mg/L.
- High yield attributed to >95% insolubility via inclusion body formation and enhanced T7 leader driven translational initiation.
Why It Matters
This optimized mini-tag strategy offers a significant advancement for the scalable and economical production of GLP-1 analogs and other therapeutic peptides. By focusing on mass fraction optimization, which minimizes the fusion-tag mass relative to the target peptide while preserving robust inclusion body formation, this approach directly addresses a major bottleneck in biomanufacturing. Developing cost-effective and high-yield production methods for complex peptides like liraglutide can reduce manufacturing expenses, potentially lowering treatment costs and improving accessibility for patients with Type 2 diabetes mellitus. This method provides a practical blueprint for future industrial-scale bioproduction of similar small therapeutic peptides.
liraglutide
peptide production
e.coli
protein engineering
biomanufacturing
glp-1 analog